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group) and 10 (metoprolol group) neurological patients who 
had received one of the drugs orally for therapeutic purpos-
es prior to lumbar puncture. We quantified their total con-
centrations by liquid chromatography/tandem mass spec-
trometry in paired serum and CSF samples.  Results: Median 
(interquartile range) in CSF reached 55% (47–64%) of total 
serum concentrations for bisoprolol and 43% (27–81%) for 
metoprolol, corresponding to 78% (67–92%) and 48% (30–
91%) of respective unbound serum concentrations.  Conclu-
sion: The extent of penetration of bisoprolol and metoprolol 
into the CSF is similar and compatible with the assumption 
that both drugs may exert direct effects in the CNS. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Beta-receptor blockers are reported to cause central 
nervous system (CNS) adverse effects in patients  [1] . Be-
sides physicochemical properties such as molecular size 
and lipophilicity, high beta(2)-receptor affinity has been 
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 Abstract 
 Background: Bisoprolol and metoprolol are moderately li-
pophilic, beta(1)-selective betablockers reported to cause 
adverse effects in the central nervous system (CNS), such as 
sleep disturbance, suggesting that both drugs may reach rel-
evant concentrations in the brain. CNS beta(2)-receptor 
blockade has been suspected to be related to such effects. 
The higher molecular size of bisoprolol (325 Dalton) and the 
higher beta(1)-selectivity compared to metoprolol (267 Dal-
ton) would suggest a lower rate of CNS effects.  Methods: To 
address the pharmacokinetic background of this assump-
tion, we quantified to which extent these beta(1)-blockers 
are able to enter the cerebrospinal fluid (CSF) in 9 (bisoprolol 
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proposed to be related to such effects  [2] . Although the 
beta(1)-selective drugs, bisoprolol and metoprolol, have 
limited beta(2) affinity, sleep disturbances are stated as 
occurring “occasionally,” corresponding to a frequency 
of <1%  [3, 4] . However, the incidence of sleep disorders 
in patients on bisoprolol is inconsistent in the literature 
with reported frequencies of 2%  [5] , 8%  [6] and 10%  [7] 
although these differences could be due to different dos-
es administered within individual trials. In the WHO 
global pharmacovigilance database, “sleep disorders and 
disturbances” related to bisoprolol (325 Dalton), which 
is more beta(1)-adrenoceptor selective than metoprolol 
(276 Dalton)  [8] was reported in 288 patients (docu-
mented since 1989), while respective reports for meto-
prolol were available for 1,343 patients (since 1977)  [9] .
 To address the pharmacokinetic background of this as-
sumption that CNS concentrations of beta-blockers may 
directly cause CNS adverse effects, the objective of the 
present study was to assess to which extent the moderately 
lipophilic bisoprolol (logP = 1.87) is able to enter the cere-
brospinal fluid (CSF) in humans compared to metoprolol 
(logP = 1.88) in neurological patients treated with the drug.
 Materials and Methods 
 We quantified total concentrations of bisoprolol and metopro-
lol in blood serum and CSF retain samples withdrawn simultane-
ously within a 20-month period at the Cologne University Hospi-
tal. The study protocol was approved by the Ethics Committee of 
Medical Faculty of the University of Cologne. All patients or their 
legal representatives gave their written informed consent to this 
use of their samples.
 Nine and 10 patients treated with bisoprolol and metoprolol, 
respectively, were identified ( Table 1 ). Of these, paired CSF and 
serum were available for 9 and 7 patients, respectively, enabling the 
calculation of a ratio. All the patients had received one of the drugs 
for therapeutic purposes not more than 24 h prior to lumbar punc-
ture. Lumbar puncture was done for diagnostic reasons in patients 
with various neurological diseases or when a neurological disease 
was suspected. In the bisoprolol group, patients included in this 
study were between 57 and 79 years (interquartile range [IQR] 
64–73 years, median 68 years); in the metoprolol group, patients 
were in the 34–80 years age range (IQR 60–75, median 69.5 years). 
Patients received standard doses ( Tables 2 ,  3 ). 
 Within the study population, no patient had severe hepatic im-
pairment that would have made dose adjustments necessary.
 To assess possible contamination of CSF with blood, semi-
quantitative estimates were done on the number of erythrocytes in 
a counting chamber containing a volume of 3.2 μL (isolated = un-
til 5 erythrocytes, + = until 90 erythrocytes, ++ = over 90 erythro-
cytes, +++ = over 350 erythrocytes, plentiful = overlying erythro-
cyte layers). Any CSF sample rated “+++” or “plentiful” or lacking 
this information was excluded from analysis. Samples were stored 
at 4   °   C until their use for routine diagnostics. Thereafter, the re-
maining portions of paired CSF and serum samples were frozen at 
–20  °  C until analysis. 
 Due to the retrospective nature of this explorative study, the 
exact time points of drug administration and lumbar puncture 
have not been documented. The prescription of bisoprolol and 
metoprolol was documented in the hospital information system; 
however, it is unknown whether bisoprolol and metoprolol in-
deed were taken at all (while this could be proved by the pres-
ence of the substances in the samples) and at which time exact-
ly. Thus, the oral intake of bisoprolol and metoprolol was as-
sumed at 8: 00 a.m. and/or at 12: 00 a.m./18: 00 p.m., according 
to the hospital’s routine. The time of lumbar puncture was as-
sumed to be 1 h prior to the time when the samples arrived in 
the laboratory, which is also documented in the hospital infor-
mation system. Results of routine diagnostics included albumin 
concentrations in serum and CNS. Since hepatically synthesized 
albumin penetrates into the CSF through passive diffusion and 
is not produced within the CNS, the CSF/serum albumin ratio 
(QALB =  n × 10 –3 ) is used as a surrogate marker for the integ-
rity of blood-CNS barriers. The reference value of QALB for 
healthy subjects <40 years is <6.5 × 10 –3 and <8 × 10 –3 for older 
subjects  [10] . 
 Total (protein-bound + unbound) bisoprolol and metoprolol 
concentrations were quantified in serum and CSF by a fully vali-
dated liquid chromatography/tandem mass spectrometry (LC-
MS/MS) method (lower limit of quantification: 0.837 ng/mL for 
serum and 1.05 ng/mL for CSF for bisoprolol and 0.465 ng/mL for 
serum and 0.455 ng/mL for CSF for metoprolol, respectively). Free 
serum concentrations were obtained by multiplying the total con-
centration of bisoprolol and metoprolol with the fraction not 
bound to proteins (0.7 for bisoprolol and 0.9 for metoprolol)  [3, 4] 
( Table 1 ). 
 The liquid chromatography systems consisted of a binary LC-
pump (Agilent 1200 Series, Agilent Technologies, Waldbronn, 
Germany) and 2 analytical columns (bisoprolol: Kinetex 2.6 μ C 18 , 
100 Å, 50 × 4.6 mm; metoprolol: Synergie 2.5 μ Polar RP 100 Å, 
50 × 4.6 mm, Phenomenex, Aschaffenburg, Germany). For both 
analytes, isocratic elution was performed with 0.1% formic acid 
and acetonitrile (bisoprolol: 50: 50, v/v, metoprolol: 60: 40, v/v). 
Determination was carried out using an AB SCIEX API 5000 triple 
quadrupole mass spectrometer (AB SCIEX, Concord, Ontario, 
Canada) and Analyst software version 1.6.2 (AB SCIEX, Concord, 
Ontario, Canada). In brief, 50 μL of each sample was placed in a 
polypropylene-tube. Samples were deproteinized with 300 μL (bi-
soprolol) or 150 μL (metoprolol) acetonitrile (containing the in-
ternal standard bisoprolol-d5); subsequently they were vortexed 
and centrifuged. The supernatant was further diluted with water 
and 10 μL for the serum or 15 μL for the CSF samples were inject-
ed into the LC-MS/MS system. The samples for bisoprolol were 
detected with MRM (Multiple Reaction Monitoring) as follows: 
precursor  → product ion for bisoprolol 326.30  → 116.30 m/z and 
for bisoprolol-d5 (internal standard) 331.10  → 121.30 m/z; for 
both analytes in positive mode. Under these conditions, bisoprolol 
and the internal standard bisoprolol-d5 eluted after approximate-
ly 1.13 and 1.12 min. The samples for metoprolol were detected 
with MRM as follows: precursor ◊ product ion for metoprolol 
268.20  → 116.10 m/z and for bisoprolole-d5 (internal standard) 
331.10  → 121.30 m/z; also in positive mode. Metoprolol and the 
internal standard bisoprolole-d5 eluted after approximately 1.16 
and 1.36 min.
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 Calibration standards and spiked quality control samples 
(SQC) were prepared by adding a defined amount of analyte-
solution to human drug-free serum or CSF. Calibration was per-
formed by weighted (1/concentration 2 ) linear regression. Lin-
earity for bisoprolol could be demonstrated over a calibration 
range from 0.8367 to 100.4 ng/mL in serum and 1.05–20.1 ng/
mL in CSF. No interferences were observed for bisoprolol and 
the internal standard. Precision and accuracy for bisoprolol sta-
tistical quality control (SQC) in serum ranged from 2.9 to 4.0% 
and 98.2 to 101.7%. In CSF, precision and accuracy ranged from 
1.0 to 2.2% and 96.4 to 102.4%, respectively. Linearity for meto-
prolol could be demonstrated over a calibration range from 
0.4653 to 502.5 ng/mL in serum and 0.455 to 80.2 ng/mL in CSF. 
No interferences were observed for metoprolol and the internal 
standard. Precision and accuracy for the metoprolol SQCs in 
serum ranged from 0.7 to 5.1% and 97.5 to 103.4%. In CSF, pre-
cision and accuracy ranged from 2.3 to 4.8% and 102.2 to 105.9%, 
respectively. 
 Results and Discussion 
 CSF concentrations relative to total serum concentra-
tions were similar for both beta-blockers and reached 
55% (IQRs 47–64%) of total serum concentrations for 
 bisoprolol and about 43% (27–81%) for metoprolol 
( Table 1 ). 
 QALB values for bisoprolol and metoprolol ranged 
from 4 to 13.1 (median: 8.2) and 5.4–25.5 (median: 7.1) × 
10 –3 , respectively, indicating a borderline impairment of 
the blood/CSF barrier, which reflects the disease status 
of the patients but does not suggest a major effect on the 
penetration of small molecule drugs into the CSF.
 Relevant contamination with blood was ruled 
out   microscopically, with only 2 of the CSF samples 
Table 1.  Concentrations of total bisoprolol and metoprolol in paired CSF and serum samples
Parameter Minimum 1st quartile Median 3rd quartile Maximum
Bisoprolol serum concentration, ng/mL (n = 9) 7.12 7.25 14.9 21.1 23.5
Bisoprolol CSF concentration, ng/mL (n = 9) 4.60 4.69 7.30 9.09 13.3
Bisoprolol ratio CSF/serum (n = 9) 0.35 0.47 0.55 0.64 0.84
Bisoprolol ratio CSF/serum free (n = 9) 0.49 0.67 0.78 0.92 1.20
Metoprolol serum concentration, ng/mL (n = 8) 7.40 8.83 27.4 53.3 64.3
Metoprolol CSF concentration, ng/mL (n = 10) 1.40 4.19 9.30 20.9 50.8
Metoprolol ratio CSF/serum (n = 7) 0.10 0.27 0.43 0.81 2.47
Metoprolol ratio CSF/serum free (n = 7) 0.11 0.30 0.48 0.91 2.78
Table 2.  Characteristics of neurological patients with oral bisoprolol administration
Pat# Age Ratio QALB Erythrocytes* 
in CSF
Estimated GFR, 
mL/min
Last dose, mg bisoprolol 
fumarate prior to LP
1 74 0.35 10.2 Negative 59.0 5
2 73 0.49 8.8 Negative 53.7 5
3 64 0.55 4.8 Isolated 97.7 5
4 66 0.64 4.0 Negative 72.8 2.5
5 57 0.57 8.8 Negative 85.2 5
6 63 0.65 7.4 Negative 101 5
7 68 0.47 13.1 Negative NA 5
8 79 0.39 8.2 Negative 26.7 2.5
9 69 0.84 5.7 Negative 92.1 10
 CSF, cerebrospinal fluid; Pat#, patient number; Ratio, ratio of CSF/serum; QALB (= n × 10–3) = CSF/serum albumin ratio; glomeru-
lar filtration rate (GFR) was estimated by the chronic kidney disease epidemiology collaboration (CKD-EPI) and Berlin Initiative Study 
(BIS1, renal function in patients 70 years and older) formula, since serum creatinine is a less reliable indicator; LP, lumbar puncture; 
NA, not available.
* To assess possible contamination of CSF with blood, semi-quantitative estimates were done on the number of erythrocytes in a 
counting chamber containing a volume of 3.2 μL (negative = 0 erythrocytes, isolated = until 5 erythrocytes, + = until 90 erythrocytes, 
++ = over 90 erythrocytes, +++ = over 350 erythrocytes, plentiful = overlying erythrocyte layers). In any CSF sample rated “+++” or 
“plentiful” or lacking this information was excluded from analysis.
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showing erythrocytes. In the bisoprolol group, 1 
 sample was showing isolated erythrocytes; in the meto-
prolol group, 1 sample was showing up to 90 erythro-
cytes.
 Both compounds are weak bases with a pKa of 9.7. The 
charged, protonated species is the dominating (about 
95% CI) form in blood and CSF. This is why the partition-
ing coefficient in buffered aqueous media (logD) is about 
–0.2  [11] at physiological pH indicating that approxi-
mately 40% of the substances are located in the lipophilic 
compartment and 60% in the aqueous, hydrophilic me-
dium. Based on the logD (pH 7.4), the low molecular 
weight and the low polar surface area of about 50 and 60 
Å 2 both beta-blockers are predicted to permeate the bar-
riers of the CNS  [1] . Indeed, available studies on meto-
prolol (number of all patients added up  n = 12) showed 
that CSF concentrations reached 41.7–100% of total se-
rum concentrations  [12–16] , which is in accordance with 
our results.
 To get a better understanding of neuropharmacoki-
netics, knowledge about the drug distribution between 
the compartments of blood, brain tissue, and CSF is es-
sential. Drugs can either pass the cell membrane and 
hence the blood brain barrier (BBB) and blood CSF 
barrier (BCSFB) by passive diffusion or make use of 
transporters (carrier-mediated or endocytosis/trans-
cytosis)  [17] . Drugs must have both small molecular 
size (<400–600 Dalton) and high lipophilicity (low hy-
drogen bonding, <7 hydrogen bonds) to be able to pen-
etrate the barriers of the CNS  [17] . There are different 
ways for a drug to reach the CSF space: one way is di-
rectly via passage across the BCSFB. The drug circulates 
through the inner CSF space into the outer CSF space, 
also known as subarachnoid space, where again part of 
it diffuses into the CNS and the other part flows into 
venous sinus blood. The other way is indirectly by pas-
sage across the BBB followed by diffusion and convec-
tion from the brain interstitial fluid to CSF. If a drug is 
present in the CSF, aforementioned pathways must be 
considered.
 The cells of the BBB lack paracellular or transcellular 
channels and no receptor or carrier is known, and this 
may cause an influx of metoprolol into the choroid plex-
us and brain endothelial cells. It is likely that the main 
path will be through the BBB, since its surface area is 
5,000-fold greater  [18] than that of the BCSFB although 
the BCSFB is leakier than the BBB  [19] . The observation 
of drug concentrations in CSF does not provide direct in-
formation on drug concentration within brain tissue  [20] 
but is rather a measure of transport across both the BBB 
and BCSFB.
 Bisoprolol, unlike metoprolol, is a major substrate of 
p-glycoprotein (P-gp; encoded by the ABCB1 gene)  [21], 
which is a transport protein trafficking drugs out of the 
Table 3.  Characteristics of neurological patients with oral metoprolol administration
Pat# Age Ratio QALB Erythrocytes* 
in CSF
Estimated 
GFR, mL/min
Last dose, mg metoprolol tartrate (T)
or succinate (S) prior to LP
1 65 0.8 5.40 Negative 97.6 200 (T)
2 51 NA 5.50 Negative 79.6 50 (T)
3 79 0.18 6.40 Negative 65.8 50 (T)
4 59 0.10 6.30 Negative 87.5 95 (S)
5 75 0.35 7.10 Negative 66.0 95 (S)
6 74 NA 7.10 + 72.7 47.5 (S)
7 34 2.47 9.40 Negative 101 71.25 (S)
8 75 NA 9.50 Negative 69.1 47.5 (S)
9 63 0.83 25.5 Negative 97.3 50 (T)
10 80 0.43 7.80 Negative 60.2 50 (T)
 CSF, cerebrospinal fluid; Pat#, patient number; Ratio, ratio of CSF/serum; QALB (= n × 10–3) = CSF/serum albumin ratio; glomeru-
lar filtration rate (GFR) was estimated by the chronic kidney disease epidemiology collaboration (CKD-EPI) and Berlin Initiative Study 
(BIS1, renal function in patients 70 years and older) formula since serum creatinine is a less reliable indicator; LP, lumbar puncture; NA, 
not available.
* To assess possible contamination of CSF with blood, semi-quantitative estimates were done on the number of erythrocytes in a 
counting chamber containing a volume of 3.2 μL (negative = 0 erythrocytes, isolated = until 5 erythrocytes, + = until 90 erythrocytes, 
++ = over 90 erythrocytes, +++ = over 350 erythrocytes, plentiful = overlying erythrocyte layers). In any CSF sample rated “+++” or 
“plentiful” or lacking, this information was excluded from analysis.
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cell  [17] . It is well recognized that P-gp may protect the 
brain from noxious substances  [22] . Within the CNS, 
this transporter is located at the apical membranes of the 
blood-CNS barriers, adluminal to the blood at the (BBB, 
brain endothelial cells)  [17] and the arachnoid barrier 
cells at the arachnoidea mater  [23] as well as adluminal 
to the CSF at the blood CSF barrier (BCSFB, epithelial 
cells of the choroid plexus)  [17] . The relative distribution 
and functionality of P-gp at the 3 barriers is unclear in 
humans. P-gp may decrease bisoprolol penetration 
through the BBB and the arachnoid barrier, but the net 
effect of bisoprolol penetration across the BCSFB re-
mains unclear. In rats, however, it was shown that con-
centrations in the CSF can be used as a surrogate for CNS 
interstitial fluid concentrations even for P-gp substrates 
 [24] . It might therefore be reasonable to assume that bi-
soprolol and metoprolol cross the BBB and BCSFB by 
passive diffusion, where for bisoprolol CNS interstitial 
and CSF concentrations may be modified in a similar 
way by P-gp.
 In serum, bisoprolol and metoprolol have a low pro-
tein binding of about 30%  [3] and 10%  [4] , respectively. 
Because CSF albumin concentrations are much lower 
than in serum ( ∼ 0.6%), the unbound fraction of both 
drugs in CSF is supposed to approximate its total con-
centration. Thus, about 78% of unbound bisoprolol and 
48% of unbound metoprolol (median values) penetrated 
the blood-CNS barrier, suggesting that, like in other or-
gans, bisoprolol and metoprolol concentrations are high 
enough in the CNS to exert some effects on beta(2) re-
ceptors although being beta(1)-selective. The selectivity 
ratio in favor of beta(1) is 13.5-fold for bisoprolol and 
2.3-fold for metoprolol as quantified using human re-
ceptors expressed on whole cells  [8] . Because CSF/se-
rum concentration ratios were similar for the 2 drugs, 
the beta(1) adrenoceptor selectivity advantage of biso-
prolol over metoprolol for cardiac effects would be es-
sentially maintained also with regard to CNS effects sup-
posed to be mediated mainly via beta(2) adrenoceptor 
blockade.
 Conclusion 
 The extent of penetration of both bisoprolol and meto-
prolol into the CSF is similar and compatible with the as-
sumption that both drugs may exert direct effects in the 
CNS.
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